



DEPARTMENT OF HEALTH & HUMAN SERVICES

---

National Institutes of Health  
Bethesda, Maryland 20892

December 21, 2016

J. Donald Easton, M.D.  
Clinical Professor  
UCSF Department of Neurology  
Sandler Neurosciences Center  
675 Nelson Rising Lane  
San Francisco, CA 94158-0663

Dear Dr. Easton:

I am writing to confirm that the NINDS-appointed Data and Safety Monitoring Board (DSMB) for your clinical trial, "Platelet-Oriented Inhibition in New TIA and minor ischemic stroke" (POINT), met by teleconference on December 16, 2016 to review all available data from the trial. The DSMB had no concerns regarding safety or study implementation, and thus recommended the trial proceed as planned.

The next teleconference of the DSMB will be scheduled for June 2017.

Sincerely,

A handwritten signature in blue ink, appearing to read "Peter R. Gilbert".

Peter R. Gilbert, Sc.M.  
Clinical Research Project Manager  
Division of Clinical Research  
National Institute of Neurological Disorders and Stroke